Research Interests
My primary research interests at this time relate to myeloproliferative neoplasms (MPN), including epidemiologic studies, translational research focused on new treatments for MPNs, and natural history studies helping us better understand disease progression in MPNs. More broadly, I am also interested in early cancer detection and the application of machine learning (ML) and other artificial intelligence (AI) methods to epidemiologic research. Finally, I retain an interest in research related to infectious diseases, global health, and global health product development.
Bio
Dr. David Shoultz is the inaugural Chief Scientific Officer (CSO) at the Myeloproliferative Neoplasm (MPN) Research Foundation. He was appointed to this role in January 2025. The mission of MPN Research Foundation is to stimulate original research in pursuit of new treatments, and eventually a cure, for the blood cancers essential thrombocythemia, polycythemia vera, and myelofibrosis, known collectively as MPN. Through a combination of investing in innovative research, advocating for the patient voice, and convening the global MPN community, the MPN Research Foundation brings together patients, researchers, and industry around the common goal of realizing new treatment options and, ultimately, cures for MPNs.
Prior to joining the MPN Research Foundation, David had most recently founded Monod Bio with Drs. Daniel Silva Manzano and Alfredo Quijano Rubio. The Company spun out of the laboratory of UW Professor of Biochemistry and Institute for Protein Design (IPD) founder Dr. David Baker in 2021; Dr. Baker was awarded the Nobel Prize for Chemistry in 2024. Before founding Monod Bio, David held multiple positions of increasing responsibility at biotech, pharmaceutical, and life sciences companies. In addition, he held significant leadership positions in global health product development at the Bill & Melinda Gates Foundation and PATH. At PATH, David was the Global Program Leader for the Drug Development Program.
David received his bachelor’s degree, M.S., and Ph.D. from the University of Washington in Seattle. His MBA is from the Albers School of Business & Economics at Seattle University, where he was previously a faculty member in the Executive MBA Program. He has been on the Affiliate Faculty at the University of Washington in the departments of Epidemiology and Global Health for more than twenty (20) years, has advised students, given guest lectures, and designed and taught courses on global health and epidemiology. He was also a member of the faculty at the Seattle University School of Business & Economics for many years; there he advised students and taught courses on strategy, operations, and health.
David’s expertise includes the development of drugs, diagnostics and vaccines. Beyond MPN, David has a special interest in other hematologic malignancies and cancers, and in infectious diseases – including those of importance in low and middle income countries (LMIC). David currently teaches courses on epidemiology in the Health Informatics and Health Information Management (HIHIM) and Masters of Health Administration (MHA) Programs at the University of Washington.
Education
PhD Epidemiology, University of Washington, 1997
MS Epidemiology, University of Washington, 1995
MBA Seattle University, 2012
BSN University of Washington, 1991
Academic Programs and Affiliations
News
Faculty-staff-retiree gifts to the University show depths of connection
University Week, 10/21/2008